Oppenheimer Downgrades Complete Genomic (GNOM) to Perform
Tweet
Share
E-mailGet Alerts GNOM Hot Sheet
Price: $58.56 -0.9%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Join SI Premium – FREE
Oppenheimer downgraded Complete Genomic (NASDAQ: GNOM) from Outperform to Perform and removes their $8 price target as disappointing preliminary 4Q11 results highlighted by further price erosion, slower-than-expected backlog growth, and another operational misstep.
For an analyst ratings summary and ratings history on Complete Genomic click here. For more ratings news on Complete Genomic click here.
Shares of Complete Genomic closed at $3.89 yesterday.
For an analyst ratings summary and ratings history on Complete Genomic click here. For more ratings news on Complete Genomic click here.
Shares of Complete Genomic closed at $3.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Downgrades Weave Communications Inc (WEAV) to Hold
- H.C. Wainwright Downgrades EyePoint Inc. (EYPT) to Neutral
- BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
